Impact of Diabetes and Glycemia on Cardiac Improvement and Adverse Events Following Mechanical Circulatory Support

Author:

Kyriakopoulos Christos P.12ORCID,Taleb Iosif12ORCID,Tseliou Eleni12ORCID,Sideris Konstantinos1ORCID,Hamouche Rana2ORCID,Maneta Eleni12ORCID,Nelson Marisca1,Krauspe Ethan1ORCID,Selko Sean1ORCID,Visker Joseph R.2ORCID,Dranow Elizabeth1ORCID,Goodwin Matthew L.1ORCID,Alharethi Rami1ORCID,Wever‐Pinzon Omar12ORCID,Fang James C.1ORCID,Stehlik Josef1ORCID,Selzman Craig H.12ORCID,Hanff Thomas C.1ORCID,Drakos Stavros G.12ORCID

Affiliation:

1. Utah Cardiac Recovery (UCAR) Program (University of Utah Health & School of Medicine, Intermountain Medical Center, and George E. Wahlen Department of Veterans Affairs Medical Center) Salt Lake City UT USA

2. Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah Salt Lake City UT USA

Abstract

Background Type 2 diabetes is prevalent in cardiovascular disease and contributes to excess morbidity and mortality. We sought to investigate the effect of glycemia on functional cardiac improvement, morbidity, and mortality in durable left ventricular assist device (LVAD) recipients. Methods and Results Consecutive patients with an LVAD were prospectively evaluated (n=531). After excluding patients missing pre‐LVAD glycated hemoglobin (HbA1c) measurements or having inadequate post‐LVAD follow‐up, 375 patients were studied. To assess functional cardiac improvement, we used absolute left ventricular ejection fraction change (ΔLVEF: LVEF post‐LVAD−LVEF pre‐LVAD). We quantified the association of pre‐LVAD HbA1c with ΔLVEF as the primary outcome, and all‐cause mortality and LVAD‐related adverse event rates (ischemic stroke/transient ischemic attack, intracerebral hemorrhage, gastrointestinal bleeding, LVAD‐related infection, device thrombosis) as secondary outcomes. Last, we assessed HbA1c differences pre‐ and post‐LVAD. Patients with type 2 diabetes were older, more likely men suffering ischemic cardiomyopathy, and had longer heart failure duration. Pre‐LVAD HbA1c was inversely associated with ΔLVEF in patients with nonischemic cardiomyopathy but not in those with ischemic cardiomyopathy, after adjusting for age, sex, heart failure duration, and left ventricular end‐diastolic diameter. Pre‐LVAD HbA1c was not associated with all‐cause mortality, but higher pre‐LVAD HbA1c was shown to increase the risk of intracerebral hemorrhage, LVAD‐related infection, and device thrombosis by 3 years on LVAD support ( P <0.05 for all). HbA1c decreased from 6.68±1.52% pre‐LVAD to 6.11±1.33% post‐LVAD ( P <0.001). Conclusions Type 2 diabetes and pre‐LVAD glycemia modify the potential for functional cardiac improvement and the risk for adverse events on LVAD support. The degree and duration of pre‐LVAD glycemic control optimization to favorably affect these outcomes warrants further investigation.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference57 articles.

1. Centers for Disease Control and Prevention . National Diabetes Statistics Report, 2020. Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020. https://www.cdc.gov/diabetes/data/statistics‐report/index.html

2. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association

3. Heart failure risk prediction in the Multi-Ethnic Study of Atherosclerosis

4. Insulin Resistance and Risk of Congestive Heart Failure

5. Diabetes and cardiovascular disease. The Framingham study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3